These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20021209)

  • 1. Emerging therapeutic targets in breast cancer bone metastasis.
    Rose AA; Siegel PM
    Future Oncol; 2010 Jan; 6(1):55-74. PubMed ID: 20021209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of targeted drug delivery system for the treatment of bone metastasis.
    Vinay R; KusumDevi V
    Drug Deliv; 2016; 23(1):21-9. PubMed ID: 24839990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of bone metastases and the benefits of bone-targeted therapy.
    Lipton A
    Semin Oncol; 2010 Oct; 37 Suppl 2():S15-29. PubMed ID: 21111244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Encounter of cancer cells with bone. Development of bone metastasis-specific targeting therapy].
    Hayashi S; Hanamura T
    Clin Calcium; 2011 Mar; 21(3):389-96. PubMed ID: 21358060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies in metastatic bone pain.
    Coluzzi F; Mandatori I; Mattia C
    Expert Opin Emerg Drugs; 2011 Sep; 16(3):441-58. PubMed ID: 21545247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone metastatic disease: taking aim at new therapeutic targets.
    Coluzzi F; Di Bussolo E; Mandatori I; Mattia C
    Curr Med Chem; 2011; 18(20):3093-115. PubMed ID: 21651483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
    Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in management of bone disease in breast cancer.
    Walkington L; Coleman RE
    Bone; 2011 Jan; 48(1):80-7. PubMed ID: 20621652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Involvement of RANKL/RANK pathway in bone metastasis in breast cancer].
    Yoneda T
    Clin Calcium; 2011 Aug; 21(8):1159-66. PubMed ID: 21814020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bisphosphonates and breast cancer].
    Vehmanen L; Saarto T
    Duodecim; 2010; 126(10):1229-37. PubMed ID: 20597352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
    Takahashi S
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer bone metastasis and current small therapeutics.
    Cicek M; Oursler MJ
    Cancer Metastasis Rev; 2006 Dec; 25(4):635-44. PubMed ID: 17160709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates in breast cancer: antitumor effects.
    Aft R
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):292-9. PubMed ID: 21558988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New molecular targets in bone metastases.
    Santini D; Galluzzo S; Zoccoli A; Pantano F; Fratto ME; Vincenzi B; Lombardi L; Gucciardino C; Silvestris N; Riva E; Rizzo S; Russo A; Maiello E; Colucci G; Tonini G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S6-S10. PubMed ID: 21129612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies in bone sarcomas: current approach and future directions.
    Yarber JL; Agulnik M
    Expert Opin Investig Drugs; 2011 Jul; 20(7):973-9. PubMed ID: 21510829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted drug delivery for breast cancer treatment.
    Jin S; Ye K
    Recent Pat Anticancer Drug Discov; 2013 May; 8(2):143-53. PubMed ID: 23394116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agents targeting prostate cancer bone metastasis.
    Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.